Roche’s Rituxan Stops Lymphoma Worsening, Study Says

Follicular lymphoma patients receiving Roche and Biogen Idec’s cancer drug Rituxan lived longer without their disease getting worse in a late stage study, the companies said.
Yahoo! Finance UK & Ireland